These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25541709)

  • 21. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
    Hong E; Giuliani MM; Deghmane AE; Comanducci M; Brunelli B; Dull P; Pizza M; Taha MK
    Vaccine; 2013 Feb; 31(7):1113-6. PubMed ID: 23261039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.
    Tzanakaki G; Hong E; Kesanopoulos K; Xirogianni A; Bambini S; Orlandi L; Comanducci M; Muzzi A; Taha MK
    BMC Microbiol; 2014 Apr; 14():111. PubMed ID: 24779381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010-2016.
    Rodrigues CMC; Lucidarme J; Borrow R; Smith A; Cameron JC; Moxon ER; Maiden MCJ
    Emerg Infect Dis; 2018 Apr; 24(4):673-682. PubMed ID: 29553330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.
    Mowlaboccus S; Perkins TT; Smith H; Sloots T; Tozer S; Prempeh LJ; Tay CY; Peters F; Speers D; Keil AD; Kahler CM
    PLoS One; 2016; 11(6):e0158315. PubMed ID: 27355628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017.
    Ceyhan M; Ozsurekci Y; Lucidarme J; Borrow R;
    Vaccine; 2020 Apr; 38(19):3545-3552. PubMed ID: 32199701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Product review on the IMD serogroup B vaccine Bexsero®.
    Deghmane AE; Taha MK
    Hum Vaccin Immunother; 2022 Dec; 18(1):2020043. PubMed ID: 35192786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China.
    Zhu B; Shi F; Zhang A; Sun X; Xu Z; Xu L; Gao Y; Lv J; Shao Z
    Vaccine; 2018 Apr; 36(15):1983-1989. PubMed ID: 29523451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation and Immunogenicity of
    Manoharan S; Farman TA; Piliou S; Mastroeni P
    Front Immunol; 2024; 15():1473064. PubMed ID: 39380985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
    Efron A; Biolchi A; Sorhouet Pereira C; Tomei S; Campos J; De Belder D; Moscoloni MA; Santos M; Vidal G; Nocita F; Vizzotti C; Pizza M
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288389. PubMed ID: 38111094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.